z-logo
Premium
Outcomes of cPRA 100% deceased donor kidney transplant recipients under the new Kidney Allocation System: A single‐center cohort study
Author(s) -
Jackson Kyle R.,
Chen Jennifer,
Kraus Edward,
Desai Niraj,
Segev Dorry L.,
Alachkar Nada
Publication year - 2020
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.15956
Subject(s) - medicine , context (archaeology) , single center , incidence (geometry) , cohort , kidney , creatinine , renal function , kidney transplantation , kidney transplant , transplantation , gastroenterology , paleontology , physics , optics , biology
In light of changes in donor/recipient case‐mix and increased cold ischemia times under the Kidney Allocation System (KAS), there is some concern that cPRA 100% recipients might be doing poorly under KAS. We used granular, single‐center data on 109 cPRA 100% deceased donor kidney transplant (DDKT) recipients to study post‐KAS posttransplant outcomes not readily available in national registry data. We found that 3‐year patient (96.4%) and death‐censored graft survival (96.8%) was excellent. We also found that cPRA 100% recipients had a relatively low incidence of T cell–mediated rejection (9.2%) and antibody‐mediated rejection (AMR) (13.8%). T cell–mediated rejection episodes tended to be relatively mild—50% (5 episodes) were grade 1, 50% (5 episodes) were grade 2, and none were grade 3. Only 1 episode was associated with graft loss, but this was in the context of a mixed rejection. Although only 15 recipients (13.8%) developed an AMR episode, 2 of these were associated with a graft loss. Despite the rejection episodes, the vast majority of recipients had excellent graft function 3 years posttransplant (median serum creatinine 1.5 mg/dL). In conclusion, cPRA 100% DDKT recipients are doing well under KAS, although every effort should be made to prevent AMR to ensure long‐term outcomes remain excellent.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here